Skip to main content


Luke Hoffman, MD, PhD

Luke Hoffman, MD, PhD

Pulmonary and Sleep Medicine, Cystic Fibrosis Research

On staff since September 2004

Academic Title: Associate Professor, Pediatrics

Research Center: Center for Clinical and Translational Research

Making a Difference

  • Possible Secret Revealed

    A discovery about how Pseudomonas interacts with Staphylococcus points the way to understanding its drug resistance and defeating chronic lung infections.... cont.


SarahKetchikan, AK11.06.11
Dr. Hoffman has been a blessing in our lives since the diagnosis of our daughter who has Cysitic Fibrosis. Dr. Hoffman has been our daughter's doctor since 4 months of age. Being from a small isolated community we have traveled countless times to the CF clinic. Dr. Hoffman has been accommodating to us due to difficult travel and has ALWAYS made time to address any questions or concerns big or small. Dr. Hoffman's passion is apparent in the way he interacts with his patients and their families. Dr. Hoffman provides excellent care and considers each step in our daughter's treatment and health maintenance plan carefully. I highly recommend him!
StephanieLynnwod, WA03.22.11
Dr. Hoffman was just a resident when he first cared for our son. Now, as an attending physician, Dr. Hoffman still provides care and consultation for our son, 13 years later. Dr. Hoffman's bedside manner is fantastic. I will always remember him crouching down to speak eye to eye with both patients and parents. His knowledge is extensive and he is always seeking to know more. Finding answers to difficult questions is a strength of Dr. Hoffman's. We highly recommend Dr. Luke Hoffman!
Recommend Dr. Luke Hoffman


Board Certification(s)
Pediatric Pulmonology
Medical/Professional School
University of California, San Francisco, San Francisco
Pediatrics, University of Washington School of Medicine, Seattle
Pediatric Pulmonology, University of Washington School of Medicine, Seattle
Research Description

We are working to understand why children with chronic lung infections don't improve with antibiotics as predicted based on our knowledge of the microbes involved. As a paradigm for this problem, we focus on the chronic lung infections in people with the genetic disease cystic fibrosis (CF), infections that usually respond incompletely to antibiotics predicted to be effective against the bacteria we know to be present. They exhibit several other characteristics common to many difficult to treat, chronic lung infections, including the following:

1) They frequently include multiple microbial species infecting together, which makes it difficult to know which of these species impact lung disease either by themselves or by interacting with other pathogenic microbes.

2) The chemical and microbial environment in which these infections occur is probably different from that used in laboratory microbial tests, including the availability of nutrients that impact microbial behavior.

Currently, our laboratory studies the behavior of the microbes causing CF and other chronic lung infections in models that attempt to more closely reflect the airway environment, which includes multiple microbial species, antibiotics, and specific nutrients. We hope to identify new and more effective treatments for children with chronic, polymicrobial lung infections, starting with CF.


Research Focus Area

Cystic Fibrosis, Pulmonary

Awards and Honors

Award NameAward DescriptionAwarded ByAward Date
Outstanding Teaching AwardUW Pediatrics Residency Program 2013
Research feature magazine 2010
Nominee, Seattle Childrens Hospital Family Choice AwardSeattle Childrens Hospital 2009
Elected ScholarInstitute for Translational Health Sciences 2008
NomineeSeattle Childrens Hospital Family Choice Award 2007
2006 First author of one of 2005s "Top Articles in Infectious Disease"Pediatric News 2006
Leroy Matthews Physician Scientist Award 2004 - 2005
Cystic Fibrosis Foundation Third-year Research Fellowship Training AwardCystic Fibrosis Foundation 2003 - 2004
Cystic Fibrosis Foundation Clinical Fellowship Second-year Training AwardCystic Fibrosis Foundation 2002 - 2003
Cystic Fibrosis Foundation Clinical Fellowship First-year Training AwardCystic Fibrosis Foundation 2001 - 2002
Young Scientist AwardOptions for the Control of Influenza III, Cairns, Australia 1996
Richard Fineberg Memorial Student Teaching AwardUCSF 1994
Medical Scientist Training Program Award 1990 - 1998
University Citation, (One of top 10 Univ. grads)UC Berkeley 1990
Departmental Citation (valedictorian)College of Chemistry, UC Berkeley 1990
Invited graduation speakerUC Berkeley 1990
Thompson Chemistry Scholarship 1988 - 1990
Regents' ScholarshipUC Berkeley 1986 - 1990


Escherichia coli Dysbiosis Correlates With Gastrointestinal Dysfunction in Children With Cystic Fibrosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America , 2013 Nov 20
Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.
Antimicrobial agents and chemotherapy , 2013 Nov: 57(11)5406-14
Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America , 2013 Aug: 57(3)384-91
What to expect when you're expectorating: cystic fibrosis exacerbations and microbiota.
Annals of the American Thoracic Society , 2013 Jun: 10(3)249-50
Interpreting infective microbiota: the importance of an ecological perspective.
Trends in microbiology , 2013 Jun: 21(6)271-6
Reducing bias in bacterial community analysis of lower respiratory infections.
The ISME journal , 2013 Apr: 7(4)697-706
Cystic fibrosis therapeutics: the road ahead.
Chest , 2013 Jan: 143(1)207-13
Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience.
Thorax , 2012 Oct: 67(10)867-73
Emerging drugs for bronchiectasis.
Expert opinion on emerging drugs , 2012 Sep: 17(3)361-78
Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2011 Dec: 10(6)387-400
Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2011 Sep: 10(5)357-65
Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.
Expert review of molecular diagnostics , 2011 Mar: 11(2)197-206
Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation.
American journal of respiratory and critical care medicine , 2010 Sep 1: 182(5)627-32
Revealing the dynamics of polymicrobial infections: implications for antibiotic therapy.
Trends in microbiology , 2010 Aug: 18(8)357-64
Exploratory study of the prevalence and clinical significance of tobramycin-mediated biofilm induction in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Antimicrobial agents and chemotherapy , 2010 Jul: 54(7)3024-6
Asymmetrical distribution of the second messenger c-di-GMP upon bacterial cell division.
Science (New York, N.Y.) , 2010 Jun 4: 328(5983)1295-7
Management of children with empyema: Pleural drainage is not always necessary.
Pediatric pulmonology , 2010 May: 45(5)475-80
Comparing the microbiota of the cystic fibrosis lung and human gut.
Gut microbes , 2010 Mar: 1(2)85-93
Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
Pediatric pulmonology , 2010 Feb: 45(2)127-34
Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airway.
PLoS pathogens , 2010 Jan 8: 6(1)e1000712
Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2009 Jan: 8(1)66-70
Attachment and Entry of Influenza Virus into Host Cells: Pivotal Roles of the Hemagglutinin
Structural Biology of Viruses , 1997
Fusion Mechanism of the Influenza Hemagglutinin: Inhibitor Design
Options for the Control of Influenza III: Proceedings , 1996
The Low pH-induced Conformational Change in the Influenza Hemagglutinin: Inhibitor Design
PhD thesis, UCSF , 1996
How aspirin works ,


Presentations TitleEventLocationDate
What to expect when youre expectorating: An ecological perspective on chronic respiratory infectionsUniversity of Minnesota Pediatrics Ground RoundsMinneapolis, MinnesotaDec. 11, 2013
CF lung microbiome: What have we learned?The 27th Annual North American Cystic Fibrosis Foundation Conference (NACFC)Salt Lake City, UtahOct. 24, 2013
Staphylococcus aureus Small-Colony Variants Are Independently Associated With Worse Lung Disease Children With Cystic FibrosisThe 36th European Cystic Fibrosis ConferenceLisbon, PortugalJune 14, 2013
Pseudomonas aeruginosa adaptation during early CF airway infection and treatmentUniversity of Washington Cystic Fibrosis Research Seminar SeriesSeattle, WAMay 9, 2013
Bacterial interspecies interactions during chronic infections: From bedside to bench, and back againMontana State University Departmental Seminar for Microbiology, Immunology, and Infectious Disease (chosen by the graduate studentsBozeman, MontanaNov. 2, 2012
Microbial Ecology and Emerging Pathogens. (Workshop Chair and speaker) The 26th Annual North American Cystic Fibrosis Foundation Conference (NACFC)Orlando, FLOct. 13, 2012
Bacterial interspecies interactions during chronic infections: From the bench to bedside, and back againUniversity of Vermont Center of Biomedical Research Excellence in Immunology and Infectious Diseases Seminar SeriesUniversity of Vermont, Burlington, VTSept. 28, 2012
Microbial interspecies interactions during chronic polymicrobial infectionsUniversity of Washington Department of Microbiology Annual RetreatUniversity of Washington, Seattle, WASept. 21, 2012
Chronic lung infections in children: Why dont antibiotics work better? University of Washington Department of Pediatrics Principal Investigator Research Seminar SeriesUniversity of Washington, Seattle, WAJune 18, 2012
The prevalence and clinical significance of Staphylococcus aureus small-colony variants in chronic CF lung infectionsQueens University Belfast School of Pharmacy Seminar SeriesQueens University Belfast, Northern IrelandJune 5, 2012
Describing the CF Gut Microbiome in Infancy and Early ChildhoodUniversity of Washington Annual CF Retreat, University of WashingtonSeattle, WAAug. 31, 2011
Bacterial adaptation during chronic infections: The role of bacterial interspecies interactionsRoss University Research Day (Entitled, "Chronic Infections: A Key Frontier in Infectious Diseases", organized by Lucas Hoffman)Ross University, DominicaJan. 21, 2011
A research approach to chronic, polymicrobial lung infectionsKings College London Molecular Microbiology Research Laboratory Research Seminar SeriesKings College London, United KingdomNov. 19, 2010
Bacterial adaptive changes during chronic, polymicrobial infections: Lessons from cystic fibrosisUniversity of Washington Microbiology Departmental Seminar, University of WashingtonSeattle, WAOct. 5, 2010
Cystic fibrosis exacerbations: A deliberately provocative examination of current antibiotic managementSeattle CF Center and Affiliate Centers Annual Clinical Conference, University of WashingtonSeattle, WashingtonJuly 23, 2010
Bacterial adaptive changes during chronic, polymicrobial infections: Lessons from cystic fibrosisStanford University Department of Pediatrics, Center for Excellence in Pulmonary Biology research seminarPalo Alto, CAFeb. 9, 2010
Bacterial Adaptation During Chronic Infections: Lessons from Cystic FibrosisUniversity of Montana Division of Biological Sciences Departmental SeminarMissoula, MTDec. 7, 2009
Evolution and BiofilmsThe 5th International American Society of Microbiology Conference on BiofilmsCancun, MexicoNov. 17, 2009
Pseudomonas aeruginosa adaptation during early cystic fibrosis infection and treatment: lasR mutationThe 23rd Annual North American CF ConferenceMinneapolis, MNOct. 10, 2009
Bacterial Adaptation During Chronic Infections: Lessons from Cystic FibrosisVanderbilt University Department of Pediatrics Research ConferenceNashville, TNOct. 5, 2009
The Adaptive Significance of Pseudomonas aeruginosa lasR Mutations in CF: Cystic Fibrosis Research Development Program Annual Retreat,Seattle, WAAug. 31, 2009
Interspecies Microbial Interactions in CF Airways: Lessons from Pseudomonas and StaphylococcusCystic Fibrosis Research Development Network Seminar SeriesSeattle, WA 2009

Research Funding

Grant TitleGrantorAmountAward Date
Baby Observational and Nutrition StudyCystic Fibrosis Foundation
Staphylococcus aureus small-colony variants: Optimal testing and treatmentCCTR
High-resolution fluorescent microscopic characterization of CF polymicrobial lung infectionsCystic Fibrosis Foundation
The relationship of fecal microbiomes and nutritional status in CFCystic Fibrosis Foundation
Describing the CF Gut Microbiome in Infancy and Early ChildhoodNIH
Community-level Physiologic Profiling of Whole Cystic Fibrosis SputumCystic Fibrosis Foundation
The roles of Staphylococcus aureus and Pseudomonas aeruginosa adapted forms in cystic fibrosis (CF) lung diseaseCystic Fibrosis Foundation
Changes in CF Respiratory Microbiota During Treatment With Kalydeco in People with the G551D MutationNIH
Pseudomonas aeruginosa adaptation During Early Cystic Fibrosis Airway Infection and TreatmentCystic Fibrosis Foundation

Primary Office

Seattle Children's
OC.7.720 - Pulmonary
4800 Sand Point Way NE
Seattle, WA 98105

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options